Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs

References

• Brown, K. L., Cosseau, C., Gardy, J. L., & Hancock, R. E. (2007). Complexities of targeting innate immunity to treat infection. Trends in Immunology, 28, 260–266.
   PubMed Web of Science ®Google Scholar
• Cornell, W. D., Cieplak, P., Bayly, C. I., Gould, I. R., Merz, K. M., Jr, Ferguson, D. M., … Kollman, P. A. (1995). A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. Journal of the American Chemical Society, 117, 5179–5197.
   Web of Science ®Google Scholar
• Dileep, K. V., Remya, C., Tintu, I., Haridas, M., & Sadasivan, C. (2013). Interactions of selected indole derivatives with Phospholipase A2: In silico and in vitro analysis. Journal of Molecular Modeling, 19, 1811–1817.
   PubMed Web of Science ®Google Scholar
• Gerd, D., & Werner, K. (2001). Cyclooxygenase inhibitors – current status and future prospects. European Journal of Medicinal Chemistry, 36, 109–126.
   PubMed Web of Science ®Google Scholar
• Halgren, T. A. (1996). Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry, 17, 490–519.
   Web of Science ®Google Scholar
• Hinz, B., & Brune, K. (2002). Cyclooxygenase-2–10 years later. Journal of Pharmacology and Experimental Therapeutics, 300, 367–375.
   PubMed Web of Science ®Google Scholar
• Hu, W., Guo, Z., Chu, F., Bai, A., Yi, X., Cheng, G., & Li, J. (2003). Synthesis and biological evaluation of substituted 2-Sulfonyl-phenyl-3-phenyl-indoles: A new series of selective COX-2 inhibitors. Bioorganic & Medicinal Chemistry, 11, 1153–1160.
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impeyand, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 79, 926–935.
   Web of Science ®Google Scholar
• Jorgensen, W. L., Maxwell, D. S., & Tirado, R. J. (1996). Development and testing of the OPLS all-atom force field on conformational energetic and properties of organic liquids. Journal of the American Chemical Society, 118, 11225–11236.
   Web of Science ®Google Scholar
• Kaminski, G. A., Friesner, R. A., Tirado, R. J., & Jorgensen, W. L. (2001). Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. Journal of Physical Chemistry B, 105, 6474–6487.
   Web of Science ®Google Scholar
• Kaufmann, W. E., Andreasson, K. I., Isakson, P. C., & Worley, P. F. (1997). Cyclooxygenase and the central nervous system. Prostaglandins, 54, 601–624.
   PubMed Web of Science ®Google Scholar
• Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., … Isakson, P. C. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384, 644–648.
   PubMed Web of Science ®Google Scholar
• Lau, C. K., Black, W. C., Belley, M., Chan, C., Charleson, S., Denis, D., … Wong, E. (1997). From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Advances in Experimental Medicine and Biology, 407, 73–78.
   PubMed Web of Science ®Google Scholar
• Leblanc, Y., Black, W. C., Chan, C. C., Charleson, S., Delorme, D., Denis, D., … Prasit, P. (1996). From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & Medicinal Chemistry Letters, 6, 731–736.
   Web of Science ®Google Scholar
• López-Parra, M., Clària, J., Planagumà, A., Titos, E., Masferrer, J. L., Woerner, B. M., … Rodés, J. (2002). Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology, 135, 891–900.
   PubMed Web of Science ®Google Scholar
• Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454, 428–435.
   PubMed Web of Science ®Google Scholar
• Minghetti, L. (2007). Role of COX-2 in inflammatory and degenerative brain diseases. SubCellular Biochemistry, 42, 127–141.
   PubMedGoogle Scholar
• Minghetti, L., & Levi, G. (1998). Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Progress in Neurobiology, 54, 99–125.
   PubMed Web of Science ®Google Scholar
• O’Banion, M. R. (1999). Cyclooxygenase-2; molecular biology, pharmacology and neurobiology. Critical Reviews in Neurobiology, 13, 45–82.
   PubMed Web of Science ®Google Scholar
• Pinheiro, R. M., & Calixto, J. B. (2002). Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation Research, 51, 603–610.
   PubMed Web of Science ®Google Scholar
• Praveen, P. N. R., Kabir, S. N., & Mohamed, T. (2010). Nonsteroidal anti-inflammatory drugs (NSAIDs): Progress in small molecule drug development. Pharmaceuticals, 3, 1530–1549.
   Google Scholar
• Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., Devito, B., Weksker, B. B., & Dannenberg, A. J. (1996). Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Research, 56, 4424–4429.
   PubMed Web of Science ®Google Scholar
• Sundy, J. S. (2001). COX-2 inhibitors in rheumatoid arthritis. Current Rheumatology Reports, 3, 86–91.
   PubMedGoogle Scholar
• Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology, 231, 232–235.
   PubMedGoogle Scholar
• Vodovotz, Y., Constantine, G., Faeder, J., Mi, Q., Rubin, J., Bartels, J., … An, G. (2010). Translational systems approaches to the biology of inflammation and healing. Immunopharmacology and Immunotoxicology, 32, 181–195.
   PubMed Web of Science ®Google Scholar
• Vodovotz, Y., Constantine, G., Rubin, J., Csete, M., Voit, E. O., & An, G. (2009). Mechanistic simulations of inflammation: Current state and future prospects. Mathematical Biosciences, 217, 1–10.
   PubMed Web of Science ®Google Scholar
• Wang, J. L., Limburg, D., Graneto, M. J., Springer, J., Hamper, J. R., Liao, S., … Carter, J. (2010). The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life. Bioorganic & Medicinal Chemistry Letters, 20, 7159–7163.
   PubMed Web of Science ®Google Scholar